Pando Bioscience

Pando Bioscience is an AI-driven synthetic biology company that specializes in enzyme engineering for the pharmaceutical industry. The company's proprietary Gen-AI platform combines generative AI, evolutionary analysis, and enzyme domain knowledge to design proteins with desired properties, enabling rapid development of high-performing, tailored enzymes that reduce costs and enhance efficiency in pharmaceutical processes.

Key features:
- AI-Driven Enzyme Engineering: Utilizes generative AI to design proteins with specific mutations that enhance multiple properties simultaneously, including activity, stability, and substrate specificity.
- Ultra-High-Throughput Screening: Employs a unique one-pot screening platform that screens 1000 times more enzymes than traditional methods, 75% faster, and 80% cheaper, converting diverse biological signals into abundant and quantifiable data under various conditions.
- Customized Protein Engineering: Offers tailored protein engineering services to improve existing enzymes and discover new ones for pharmaceutical companies.
- Sustainable Processes: Promotes environmentally friendly approaches by reducing the need for trial-and-error methods and minimizing the environmental impact of traditional enzyme engineering.

How it works:
1. The Gen-AI platform designs proteins with specific mutations based on desired properties.
2. The ultra-high-throughput screening platform tests the AI-generated enzyme designs using uniquely engineered yeast.
3. Billions of sequences are swiftly screened to identify the best ones for targeted protein functions.
4. Results are analyzed and optimized enzymes are delivered to clients.

Integrations:
- Proprietary Protein Databases
- High-Throughput Experimental Platform

Use of AI:
Pando Bioscience's Gen-AI platform leverages generative AI trained on large datasets of enzyme sequences and properties. This AI predicts and designs novel enzymes with desired characteristics, streamlining the enzyme engineering process.

AI foundation model:
The Gen-AI platform is built on a proprietary generative AI model specifically trained for enzyme engineering tasks.

Target users:
- Pharmaceutical companies
- Diagnostic companies
- Biotech companies

How to access:
Pando Bioscience offers its services through a web application, allowing users to access its AI-driven enzyme engineering capabilities and ultra-high-throughput screening platform online. Pricing is tailored to the specific needs of pharma companies, with customized packages for enzyme engineering and screening services.

Company background:
Pando Bioscience was founded in 2023 by Will Cao (CEO) and Yang (CTO). Cao has a background in engineering bacteria and has published papers in Cell and Nature Biotechnology. Yang brings expertise in enzyme science, bioinformatics, machine learning, systems biology, genetics, and high-throughput automation. The company has received $9.35 million in funding, with the most recent round being $500,000 in convertible notes.